Ten Major Awards Announced: 2018 Sina Medicine Annual Ranking Opens for Submissions

2018 marked the 40th anniversary of China’s reform and opening-up. In the pharmaceutical industry, which has been continuously surging with the tide of “transformation” each year, the force of “change” appeared even more potent in 2018, driven by policy adjustments, innovative technologies, and capital momentum.

To document the trajectory of transformative change in our times and uncover the power of role models, Sina Medicine officially launched the “2018 Sina Medicine Annual Awards” selection campaign on November 5. Adhering to the principle of maximizing influence and value, this initiative continuously integrates media resources. It has also invited more than ten authoritative media organizations to participate and bear witness, including VCBeat, Sai Bailan, E-Drug Manager, PR Newswire, Pharmadl, Insight Database, Firestone Creation, MedSci, Yaozhi, BioExplorer, Bio360, Yigu, Siqi Circle, CPhI Online, 39 Health Network, Health界 (Health World), First Pharmacy Financial Intelligence, and Pharmacy Manager, thereby striving to enhance synergy and brand influence.

The selection event features four award categories and ten top lists, covering major sectors of the 2018 pharmaceutical industry, including manufacturing, commerce, and retail. The event is currently in full swing with registrations open; eligible enterprises and individuals are warmly encouraged to apply.

I) 2018 China Pharmaceutical Industry Outstanding Contribution Figures

Evaluation Criteria:

1. The enterprise where the candidate is employed must be a formally registered entity within China;

2. The candidates shall possess significant influence and public recognition within China's pharmaceutical industry and related fields;

3. Nominees have demonstrated outstanding performance and made exceptional contributions to China’s pharmaceutical industry and related fields;

4. The nominee demonstrates unique philosophies in corporate management and team building, with their achievements serving as an industry benchmark.

II) Top 10 Pioneering Figures in China’s Pharmaceutical Industry in 2018

Evaluation Criteria:

1. The enterprise where the candidate is employed must be a formally registered entity within China;

2. The nominees possess a certain level of influence and public recognition within China’s pharmaceutical industry and related fields;

3. The nominees have demonstrated outstanding performance and made remarkable contributions to China’s pharmaceutical industry and related fields;

4. The nominees have actively explored and achieved certain results in business management, product development, technological innovation, etc., promoting industry progress.

3) The Most Influential Enterprises in China's Pharmaceutical Industry in 2018

Evaluation Criteria:

1. Participating enterprises must be formally registered entities within the territory of China;

2. The participating enterprises wield significant influence in China’s pharmaceutical industry and have played a prominent role in advancing the development of the sector;

3. The participating enterprise holds a high market share, demonstrates outstanding performance, and possesses core competitive advantages;

4. Participating enterprises have established a strong brand image through high-quality products and services during their development, achieving high brand awareness and reputation.

4) The Most Innovative Enterprises in China’s Pharmaceutical Industry in 2018

Evaluation Criteria:

1. Participating enterprises must be formally registered within the territory of China;

2. Eligible enterprises include, but are not limited to, those in various sub-sectors such as pharmaceutical manufacturing, pharmaceutical distribution, Internet-plus healthcare, healthcare investment, health insurance, and medical diagnostics;

3. The innovative achievements of the participating enterprises have garnered widespread attention and possess industry-driving influence;

4. Participating enterprises have established a strong brand image during their development, with high brand awareness and favorable reputation.

5) 2018 Chinese Ethnic Medicine Brand Enterprises

Evaluation Criteria:

1. Participating enterprises must be formally registered within the territory of China;

2. The products and services of the participating enterprises are guided by the theories and practices of traditional ethnic medicine, and have achieved outstanding results in the inheritance and innovation of ethnic medicine;

3. The participating enterprises have demonstrated outstanding performance in areas such as cultural dissemination and brand building;

4. The participating enterprises boast high market share and core competitive advantages, driving local economic progress.

6) 2018 China's Most Promising Smart Pharmacy

Evaluation Criteria:

1. The enterprise to which the project under evaluation belongs is a formally registered entity within the territory of China;

2. The participating project has made demonstrative attempts in "Internet + Health Services" and achieved relatively rapid growth within a certain period;

3. The project under evaluation can provide effective solutions to address market health needs and promote the sustainable development of the industry;

4. The evaluated project has achieved a positive market response during its implementation and has been widely recognized by the industry.

7) 2018 Outstanding Public Welfare Projects by Pharmaceutical Companies

Evaluation Criteria:

1. The enterprise to which the project under evaluation belongs is a formally registered enterprise within China;

2. The enterprise to which the evaluated project belongs enjoys high visibility and a strong reputation in China’s pharmaceutical industry, and holds a certain market share;

3. The evaluated project is a public relations practice activity in which the enterprise sponsors and supports health-related public welfare initiatives through contributions of human resources, material resources, and funding;

4. The project under evaluation has demonstrated significant practical effectiveness and exerted a certain degree of social impact.

8) 2018 Most Socially Responsible Listed Pharmaceutical Company

Evaluation Criteria:

1. The participating enterprises are formally registered within the territory of China;

2. Participating companies must be publicly listed, with strong recognition and reputation in the capital markets, and hold a certain market share;

3. Participating enterprises, while generating profits and fulfilling their responsibilities to shareholders, effectively safeguard employee rights and occupational health, thereby maintaining a strong reputation;

4. Participating enterprises shall prioritize production safety, operate with integrity and in compliance with laws and regulations, actively engage in public welfare initiatives, and serve as positive social role models while promoting environmental protection.

Selection Criteria for the Eight Major Awards:

The final list of awardees will be determined by a composite score comprising two components: online voting (weighted at 60%) and review by the Organizing Committee (weighted at 40%). The Organizing Committee conducts the selection in accordance with the principles of “authority, impartiality, fairness, and transparency.” Any fraudulent practices, such as soliciting votes or manipulating voting through improper means, are strictly prohibited; upon detection by monitoring systems, the offending participant’s eligibility will be disqualified. Sina Pharmaceutical News reserves the final right of interpretation for this event.

9) 2018 Sina Medicine Outstanding Author

Nomination Method: Based on official statistics from Sina Medicine regarding authors' submission volumes, readership figures, and other metrics, the top 20 in the comprehensive rankings are nominated.

10) Sina Medicine’s Most Influential Column of 2018

Nomination Method: The top 20 nominees will be selected based on a comprehensive ranking of metrics such as the number of submissions and page views in Sina Medicine’s official statistics column.

Selection Rules for the Sina Medicine Author Column Award:

Submissions and views collectively account for 50%, online voting accounts for 30%, and the organizing committee’s evaluation accounts for 20%.

Apart from the Sina Medicine Author Column Award, all other awards are open for application provided that the eligibility criteria are met.

Registration Method:

① Follow the official Sina Medicine WeChat account (sinayiyao) and click on the menu “2018 Awards” to register.

② Direct email registration: Compose an email and send it to yiyaoxinlang@sina.com, with the subject line indicating “2018 Selection + Award Name + Registration”.

Note: The email must include the award being applied for, a high-resolution logo and photo of the applying enterprise or individual, a statement of rationale (no more than 300 words), and contact information.

③ Scan the QR code below to visit the official Sina Medicine website and register.

Registration Link: http://med.sina.com/article_detail_103_1_55313.html

Registration Period: November 5, 2018–December 2, 2018

Inquiry Hotline: 010-61934050-818 (812)

Sina Pharmaceutical News

VCBeat, SAI Blue, E-Drug Manager, PR Newswire, MedSci, BioExplore, Bio360, YiGu, Siqi Circle, CPhI Online, 39 Health, Health界, First Pharmacy Finance & Intelligence, Pharmacy Manager……

Pharmadex, Insight Database, Firestone Creation, YAOZHI